Accurate onsite profiling of fluoroquinolone antibiotics (FQs) is of vital significance for ensuring food safety and estimating environmental pollution. Here, we propose a smartphone-based QD ratiometric fluorescence-sensing system to precisely report the level of FQs. As a proof of concept, we chose gatifloxacin (GFLX, a typical member of FQs) as the model for the analytical target, which could effectively trigger the fluorescence color variation of QDs from bright yellow-green (∼557 nm) to blue (∼448 nm) through the photoinduced electron-transfer (PET) process, thus yielding an evident ratiometric response. Based on this, the level of GFLX can be reported within a wide linear range from 0.85 nM to 3.6 μM. Moreover, this assay owns a high sensitivity with a low detection limit of 0.26 nM for GFLX and a quick sample-to-answer monitoring time of 5.0 min, manifesting that this platform could be fully qualified for onsite requirements. Interestingly, this portable device has successfully been applied for the onsite detection of GFLX in real food (i.e., milk and drinking water) and environmental (i.e., fish-farming water) samples with acceptable results. This developed platform offers a great promise for the point-of-care detection of FQ residues in practical application with the merits of being label-free, low-cost, and rapid, thus opening a new pathway for the onsite evaluation of food safety and environmental health.

Background As a new epigenetic biomarker, 5‐hydroxymethylcytosine (5hmC) is broadly involved in various diseases including cancers. However, the function and diagnostic performance of 5hmC in colorectal cancer (CRC) remain unclear. Results High‐throughput sequencing was used to profile 5hmC levels in adjacent normal colon, advanced adenomas, and CRC. The expression and 5hmC levels in zw10 kinetochore protein (ZW10) were significantly increased in the tissues and blood samples for patients with advanced adenoma and CRC, and were much higher in the early stages of CRC (I and II). The receiver operating characteristic analysis had potential diagnostic value for CRC. The area under the curve (AUC) of ZW10 5hmC levels in tissue samples of CRC was 0.901. In blood samples, the AUC was 0.748 for CRC. In addition, the ZW10 5hmC level had much higher diagnostic performance in early stages of CRC (AUC = 0.857) than it did in advanced stages (AUC = 0.594). Compared with FHC cell, ZW10 expression in HT29 cell was significantly increased. The ZW10 knockdown could inhibit cell proliferation and the ZW10 overexpression could promote cell proliferation in HT‐29 cell. Furthermore, ZW10 knockdown inhibited AKT and mTOR phosphorylation, and ZW10 overexpression promoted AKT and mTOR phosphorylation. Conclusions The ZW10 5hmC level may serve as an effective epigenetic biomarker for minimally invasive screening and diagnosis of CRC, and it has higher diagnostic performance in early stages of CRC than it does in advanced stages. In addition, ZW10 could regulate CRC progression through the AKT‐mTOR signaling.

No abstract

No abstract

Background Non-alcoholic fatty liver disease (NAFLD) is a common chronic liver disease characterized by excessive fat accumulation in the liver. One of the underlying pathophysiological mechanisms is insulin resistance (IR). Traditional Chinese medicine (TCM) has showed potential benefits in the management of NAFLD. Lingguizhugan decoction (LGZG) is a representative Chinese herbal formula; however, there is still no rigorous clinical trial supporting its application. Methods/design This study will be a three-arm, dose-optimization, randomized, double-blinded, placebo-controlled clinical trial. A total of 243 patients with NAFLD will be recruited and randomly assigned to the standard dose LGZG (SLGD) group, low dose LGZG (LLGD) group, or the placebo group based on a ratio of 1:1:1. The treatment period will be 12 weeks and the follow-up period will last 4 weeks. The primary outcome will be the proportions of participants with at least a 1-unit decrease of HOMA-IR from baseline to 12 weeks. Secondary outcomes will include the changes of body weight, body mass index, liver function, blood lipid metabolism, blood glucose metabolism, inflammatory responses, liver-kidney echo ratio by ultrasound, and various scales. Biological samples will also be collected for future researches on mechanism exploration. Discussion This study will provide initial evidence regarding the efficacy and safety of LGZG in the treatment of NAFLD with spleen-yang deficiency pattern and promote its application in community healthcare centers. In addition, potential mechanisms will be explored based on studies of oral and gut microbiota. Trial registration Chinese Clinical Trial Registry, ChiCTR1800014364. Registered on 1 January 2018. The final protocol version was V3.0.